About this trial
This study aims to evaluate the accuracy and safety of a novel endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement technique in 42 adults with liver cirrhosis and portal vein thrombosis (blood clots in the liver's main vein), a condition where current standard testing (HVPG) fails to provide reliable pressure readings. Participants will undergo both EUS-PPG (using a specialized needle under ultrasound guidance) and HVPG procedures to compare results; EUS-PPG will be performed under general anesthesia in a left-side lying position-an innovative approach-while also enabling immediate endoscopic treatment of bleeding veins if detected during the same session. The primary goals are to validate EUS-PPG's safety in this high-risk group, establish its correlation with HVPG, and pioneer an integrated diagnosis-treatment protocol to reduce hospital stays and costs. The study runs from July 2025 to June 2027 at Zhejiang University School of Medicine.
Eligibility criteria
Qualifiers
Age ≥ 18 years old
History of liver cirrhosis
INR < 1.5
Platelet count > 50 × 10⁹/L
Disqualifiers
Patients with ascites
Patients with renal insufficiency
Patients with active infection
Patients with hepatic encephalopathy
Trial design
Treatments tested in this trial
- endoscopic ultrasound-guided portal pressure gradient
Treatment groups
Locations
Sponsors and collaborators
Zhejiang University
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborator